მიკრო-რნმ-ები: მათი პროგნოზული როლი და მნიშვნელობა გესტაციური დიაბეტის ადრეულ დიაგნოსტიკაში

LALI LACHASHVILI; MAIA KHUBUA; MIKHEIL JANGAVADZE; ZANDA BEDINASHVILI

doi:10.52340/jecm.2026.02.09

Authors

LALI LACHASHVILI Ivane Javakhishvili Tbilisi State University
MAIA KHUBUA Ivane Javakhishvili Tbilisi State University
MIKHEIL JANGAVADZE Ivane Javakhishvili Tbilisi State University
ZANDA BEDINASHVILI Aleqsandre Natishvili Institute of Morphology, TSU, Tbilisi, Georgia

DOI:

https://doi.org/10.52340/jecm.2026.02.09

Keywords:

gestational diabetes, microRNAs, hyperglycemia, prognosis, early diagnosis

Abstract

Gestational diabetes mellitus (GDM) is a common pregnancy complication affecting mother and child, typically diagnosed in mid-pregnancy, using fasting glucose and oral glucose tolerance tests. This review examines experimental, clinical, and review studies on circulating and tissue-specific miRNAs involved in metabolic regulation, insulin signaling, inflammation, placental function. MiRNAs involved in GDM change significantly before disease is diagnosed and they may be useful as stable, noninvasive markers for early detection and prediction of the disease.

Downloads

Download data is not yet available.

Author Biographies

LALI LACHASHVILI, Ivane Javakhishvili Tbilisi State University

Faculty of Medicine

MAIA KHUBUA, Ivane Javakhishvili Tbilisi State University

Faculty of Medicine

MIKHEIL JANGAVADZE, Ivane Javakhishvili Tbilisi State University

Faculty of Medicine, Ivane Javakhishvili Tbilisi State University, Tbilisi, Georgia

Aleqsandre Natishvili Institute of Morphology, TSU, Tbilisi, Georgia

References

Dłuski D. F. et al., “Evolution of gestational diabetes mellitus across continents in 21st Century,” J. Environ. Res. Public Health, vol. 19, 2022, doi: 10.3390/ijerph192315804.

Eades C. E., Cameron D. M., Evans J. M. M., “Prevalence of gestational diabetes mellitus in Europe: A meta-analysis,” Diabetes Res. Clin. Pract., Jul. 2017;129:173–181. doi: 10.1016/j.diabres.2017.03.030.

Szmuilowicz E. D., Josefson J. L., and Metzger B. E., “Gestational Diabetes Mellitus,” Endocrinol. Metab. Clin. North Am., vol. 48, no. 3, pp. 479–493, Sep. 2019, doi: 10.1016/j.ecl.2019.05.001.

Metzger B. E. et al., “Hyperglycemia and adverse pregnancy outcome (HAPO) study,” Diabetes, vol. 58, no. 2, pp. 453–459, Feb. 2009, doi: 10.2337/db08-1112.

Yu Y. et al., “Maternal diabetes during pregnancy and early onset of cardiovascular disease in offspring: population based cohort study with 40 years of follow-up,” BMJ, p. l6398, Dec. 2019, doi: 10.1136/bmj.l6398.

Reece E. A., “The fetal and maternal consequences of gestational diabetes mellitus.,” J. Matern. Fetal. Neonatal Med., vol. 23, no. 3, pp. 199–203, Mar. 2010, doi: 10.3109/14767050903550659.

Ornoy A., Becker M., Weinstein-Fudim L., Ergaz Z. “Diabetes during pregnancy: A maternal disease complicating the course of pregnancy with long-term deleterious effects on the offspring. A clinical review,” Int. J. Mol. Sci., vol. 22, no. 6, p. 2965, Mar. 2021, doi: 10.3390/ijms22062965.

Hod M. et al., “The International federation of gynecology and obstetrics (FIGO) Initiative on gestational diabetes mellitus: A pragmatic guide for diagnosis, management, and care #,” International Journal of Gynecology&Obstetrics, Oct. 2015;131(S3):173–211. doi: 10.1016/S0020-7292(15)30033-3.

Riskin-Mashiah S., Younes G., Damti A., Auslender R. “First-trimester fasting hyperglycemia and adverse pregnancy outcomes,” Diabetes Care, Sep. 2009;32(9):1639–1643. doi: 10.2337/dc09-0688.

Lu J. and Clark A. G., “Impact of microRNA regulation on variation in human gene expression,” Genome Res., vol. 22, no. 7, pp. 1243–1254, Jul. 2012, doi:10.1101/gr.132514.111.

Ling C. and Rönn T., “Epigenetics in human obesity and type 2 diabetes,” Cell Metab., vol. 29, no. 5, pp. 1028–1044, May 2019, doi: 10.1016/j.cmet.2019.03.009.

He L. and Hannon G. J., “MicroRNAs: small RNAs with a big role in gene regulation.,” Nat. Rev. Genet., vol. 5, no. 7, pp. 522–31, Jul. 2004, doi: 10.1038/nrg1379.

Mattick J. S., “The genetic signatures of noncoding RNAs,” PLoS Genet., vol. 5, no. 4, p. e1000459, Apr. 2009, doi: 10.1371/journal.pgen.1000459.

Cortez M. A., Bueso-Ramos C., et al. “MicroRNAs in body fluids—the mix of hormones and biomarkers,” Nat. Rev. Clin. Oncol., Aug. 2011;8(8):467–477. doi: 10.1038/nrclinonc.2011.76.

Okamura K., Hagen J. W., et al. “The mirtron pathway generates microRNA-class regulatory RNAs in Drosophila.,” Cell, vol. 130, no. 1, pp. 89–100, Jul. 2007, doi: 10.1016/j.cell.2007.06.028.

Yang X., Wu N., “MicroRNAs and exosomal microRNAs may be possible targets to investigate in gestational diabetes mellitus,” Diabetes Metab. Syndr. Obes., vol. Volume 15, pp. 321–330, Feb. 2022, doi: 10.2147/DMSO.S330323.

Dinesen S., El-Faitarouni A., et al., “Circulating microRNA as biomarkers for gestational diabetes mellitus—A systematic review and meta-analysis,” Int. J. Mol. Sci., vol. 24, no. 7, p. 6186, Mar. 2023, doi: 10.3390/ijms24076186.

Page et al M. J., “PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews,” BMJ, p. n160, Mar. 2021, doi: 10.1136/bmj.n160.

Kunysz M., Cieśla M., and Darmochwał-Kolarz D., “Evaluation of miRNA expression in patients with gestational diabetes mellitus: Investigating diagnostic potential and clinical implications,” Diabetes, metabolic syndrome and obesity, vol. 17, pp. 881–891, 2024, doi: 10.2147/DMSO.S443755.

Guan C.-Y., Tian S., Cao J.-L., Wang X.-Q., Ma X., and Xia H.-F., “Down-Regulated miR-21 in Gestational Diabetes Mellitus Placenta Induces PPAR-α to Inhibit Cell Proliferation and Infiltration.,” Diabetes metab. syndr. obes., vol. 13, pp. 3009–3034, Aug. 2020, doi: 10.2147/DMSO.S253920.

Balci S., Gorur A., et al., “Expression level of miRNAS in patients with gestational diabetes,” Turkish Journal of Biochemistry, vol. 45, no. 6, pp. 825–831, Dec. 2020, doi: 10.1515/tjb-2019-0157.

Tagoma A., et al “MicroRNA profiling of second trimester maternal plasma shows upregulation of miR-195-5p in patients with gestational diabetes.,” Gene, vol. 672, pp. 137–142, Sep. 2018, doi: 10.1016/j.gene.2018.06.004.

Wander P. L. et al., “Circulating early- and mid-pregnancy microRNAs and risk of gestational diabetes.,” Diabetes Res. Clin. Pract., vol. 132, pp. 1–9, Oct. 2017, doi: 10.1016/j.diabres.2017.07.024.

Abdeltawab A., et al., “Circulating micro RNA-223 and angiopoietin-like protein 8 as biomarkers of gestational diabetes mellitus.,” Br. J. Biomed. Sci., vol. 78, no. 1, pp. 12–17, Jan. 2021, doi: 10.1080/09674845.2020.1764211.

Jamalpour S. et al., “Analysis of serum circulating MicroRNAs level in Malaysian patients with gestational diabetes mellitus.,” Sci. Rep., Nov. 2022;12(1):20295. doi: 10.1038/s41598-022-23816-3.

Razo-Azamar M. et al., “Early-pregnancy serum maternal and placenta-derived exosomes miRNAs vary based on pancreatic β-Cell function in GDM,” J. Clin. Endocrinol. Metab., vol. 109, no. 6, pp. 1526–1539, May 2024, doi: 10.1210/clinem/dgad751.

Arboleda Borrero A. M., García-Perdomo H. A., and Mosquera Escudero M., “Relationship between microRNA expression profiling and gestational diabetes: A systematic review,” Obes. Med., vol. 39, p. 100487, May 2023, doi: 10.1016/j.obmed.2023.100487.

Légaré C. et al., “First trimester plasma microRNA levels predict risk of developing gestational diabetes mellitus,” Front. Endocrinol. (Lausanne)., Nov. 2022; 13:928508, , doi: 10.3389/fendo.2022.928508.

Satake E., Pezzolesi M. G., et al. “Circulating miRNA profiles associated with hyperglycemia in patients with type 1 diabetes,” Diabetes, vol. 67, no. 5, pp. 1013–1023, May 2018, doi: 10.2337/db17-1207.

Jayabalan N. et al., “Cross talk between adipose tissue and placenta in obese and gestational diabetes mellitus pregnancies via exosomes,” Sep. 27, 2017, Frontiers Media S.A. doi: 10.3389/fendo.2017.00239.

Gillet V. et al., “miRNA profiles in extracellular vesicles from serum early in pregnancies complicated by gestational diabetes mellitus,” 2019, doi: 10.1210/jc.2018-02693.

Ibarra A., Vega-Guedes B., et al., “Diabetes in pregnancy and microRNAs: promises and limitations in their clinical application,” Noncoding RNA, vol. 4, no. 4, p. 32, Nov. 2018, doi: 10.3390/ncrna4040032.

Hocaoglu M. et al., “Identification of miR-16-5p and miR-155-5p microRNAs differentially expressed in circulating leukocytes of pregnant women with polycystic ovary syndrome and gestational diabetes,” Gyn. Endocrinology, Mar. 2021; 37(3):216–220. doi: 10.1080/09513590.2020.1843620.

Filardi T. et al., “Identification and validation of miR-222-3p and miR-409-3p as plasma biomarkers in gestational diabetes mellitus sharing validated target genes involved in metabolic homeostasis.,” Int. J. Mol. Sci., vol. 23, no. 8, p. 4276, Apr. 2022, doi: 10.3390/ijms23084276.

Joglekar M. V et al., “Postpartum circulating microRNA enhances prediction of future type 2 diabetes in women with previous gestational diabetes.,” Diabetologia, vol.64, no.7, pp.1516–1526, Jul.2021, doi:10.1007/s00125-021-05429-z.